tiprankstipranks
Advertisement
Advertisement
Adma Biologics sees FY26 revenue $530M-$560M, consensus $629.1M
PremiumThe FlyAdma Biologics sees FY26 revenue $530M-$560M, consensus $629.1M
16d ago
Analyst Reaffirms Buy Rating on ADMA Biologics, Citing Expanded Asceniv FDA Label and Strong Growth Outlook Despite Bivigam Concerns
Premium
Ratings
Analyst Reaffirms Buy Rating on ADMA Biologics, Citing Expanded Asceniv FDA Label and Strong Growth Outlook Despite Bivigam Concerns
17d ago
Adma Biologics announces FDA approval for Asceniv sBLA
Premium
The Fly
Adma Biologics announces FDA approval for Asceniv sBLA
18d ago
Adma Biologics initiated with a Buy at Canaccord
PremiumThe FlyAdma Biologics initiated with a Buy at Canaccord
1M ago
Adma Biologics price target lowered to $24 from $30 at Mizuho
Premium
The Fly
Adma Biologics price target lowered to $24 from $30 at Mizuho
1M ago
Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
Premium
The Fly
Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
2M ago
Adma Biologics falls -19.9%
PremiumThe FlyAdma Biologics falls -19.9%
2M ago
Cantor downgrades Adma Biologics on lack of clarity post short report
Premium
The Fly
Cantor downgrades Adma Biologics on lack of clarity post short report
2M ago
Adma Biologics says Culper report contains ‘inaccurate statements’
Premium
The Fly
Adma Biologics says Culper report contains ‘inaccurate statements’
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100